TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18593741

Group type: EXPERIMENTAL
Intervention: 20,000 IU cholecalciferol/week for 9 months
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 20,000 IU cholecalciferol/month during maintenance phase
Number of subjects: 64

Group type: COMPARATOR
Intervention: Untreated group (no cholecalciferol) during maintenance phase
Number of subjects: 64
Study: 15957842

Group type: EXPERIMENTAL
Intervention: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 30 mg daily
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 20 mg daily
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 10 mg daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (only medicated with JBG)
Number of subjects: 140
Study: 11846197

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMP) with simplified papilla preservation (SPP) technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Titanium-reinforced ePTFE membranes with SPP technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Access flap control procedure (SPP technique)
Number of subjects: 90
Study: 10091737

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy (6 courses)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no systemic adjuvant treatment)
Number of subjects: 39
Study: 7751496

Group type: EXPERIMENTAL
Intervention: Relaxation-biofeedback training with propranolol (60, 120, or 180 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Relaxation-biofeedback training alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Relaxation-biofeedback training with propranolol
Number of subjects: 33
Study: 2311595

Group type: EXPERIMENTAL
Intervention: Glucose polymer drink containing electrolytes (GP; 7% CHO, 231 mosmol.kg‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Electrolyte placebo drink without carbohydrate (EP; 48 mosmol.kg‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non‐electrolyte placebo (NEP; 31 mosmol.kg‐1)
Number of subjects: 9
Study: 6765502

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31648072

Group type: COMPARATOR
Intervention: Filtered air control
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cookstove treatments
Number of subjects: 48
Study: 31171031

Group type: EXPERIMENTAL
Intervention: early patient-directed rehabilitation
Number of subjects: 76

Group type: COMPARATOR
Intervention: standard rehabilitation incorporating sling immobilisation
Number of subjects: 76
Study: 30057406

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m2
Number of subjects: 126

Group type: COMPARATOR
Intervention: Gemcitabine 900 mg/m2 and docetaxel 75 mg/m2
Number of subjects: 126
Study: 27502725

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus second-line chemotherapy
Number of subjects: 494

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 494
Study: 23959095

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (500μg) and clonidine (75μg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 100
Study: 21997458

Group type: EXPERIMENTAL
Intervention: Olympic weightlifting (OL) training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Traditional weight (TW) training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 26
Study: 19151995

Group type: EXPERIMENTAL
Intervention: DVD
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control
Number of subjects: 212
Study: 18063879

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 6 mg/m2 and standard-dose cytarabine 100 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m2 with standard- and high-dose cytarabine and anthracyclines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m2 and high-dose cytarabine 3 g/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) within a reduced-intensity conditioning protocol applying fludarabine and total body irradiation
Number of subjects: 0
Study: 15189542

Group type: EXPERIMENTAL
Intervention: Double marker-guided venipuncture of extrathoracic subclavian and/or axillary vein
Number of subjects: 0
Study: 11742463

Group type: EXPERIMENTAL
Intervention: Polyethylene liner THA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metal liner THA
Number of subjects: 150
Study: 9509824

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 8214926

Group type: EXPERIMENTAL
Intervention: misoprostol (200 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 3301417

Group type: EXPERIMENTAL
Intervention: Intracervical artificial insemination (IC‐AIH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intrauterine artificial insemination (IU‐AIH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Timed vaginal intercourse
Number of subjects: 20
Study: 30361792

Group type: EXPERIMENTAL
Intervention: Ultramicronized palmitoylethanolamide 600 mg twice daily for 60 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 27886729

Group type: EXPERIMENTAL
Intervention: Social capital intervention
Number of subjects: 52
Study: 25503265

Group type: EXPERIMENTAL
Intervention: Active arm (FTC/Tenofovir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23841295

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam and Fentanyl
Number of subjects: 40
Study: 20214687

Group type: EXPERIMENTAL
Intervention: Transcutaneous partial pressure of carbon dioxide (PtCO(2)) device
Number of subjects: 24

Group type: COMPARATOR
Intervention: Arterial blood gas
Number of subjects: 24
Study: 18765504

Group type: EXPERIMENTAL
Intervention: Warfarin exposure (1-month time window)
Number of subjects: 4028

Group type: EXPERIMENTAL
Intervention: Warfarin exposure (1 to 3 prescriptions in the previous year)
Number of subjects: 4028

Group type: EXPERIMENTAL
Intervention: Warfarin exposure (1-year time window using case-time-control approach)
Number of subjects: 4028
Study: 16443871

Group type: EXPERIMENTAL
Intervention: IMPACT intervention (depression collaborative care program)
Number of subjects: 418
Study: 14752343

Group type: EXPERIMENTAL
Intervention: Amicar (epsilon aminocaproic acid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no Amicar)
Number of subjects: 36
Study: 11391748

Group type: EXPERIMENTAL
Intervention: Intravenous amantadine (200 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8607888

Group type: EXPERIMENTAL
Intervention: 300 mg oral pamidronate/day
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 1393807

Group type: EXPERIMENTAL
Intervention: Peribulbar injection (group 1)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection (group 2)
Number of subjects: 79
Study: 2856908

Group type: EXPERIMENTAL
Intervention: Cimetidine (1.0 mg/kg X h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine (0.16 mg/kg X h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30782696

Group type: EXPERIMENTAL
Intervention: Physiotherapy-led NIV sessions (5 sessions of 30 minutes each)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Continuous high-flow nasal oxygen therapy (usual care)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Physiotherapy-led NIV
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy
Number of subjects: 130
Study: 29415145

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26897504

Group type: EXPERIMENTAL
Intervention: Educational intervention (3 interactive workshops on prevention of cardiovascular disease)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (information by post)
Number of subjects: 320
Study: 23957715

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab (12 months or 9 weeks)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No adjuvant trastuzumab
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 1500
Study: 22519853

Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito nets (ITNs) protection from birth (group A)
Number of subjects: 3387

Group type: COMPARATOR
Intervention: Insecticide-treated mosquito nets (ITNs) protection from age 6 months (group B)
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 3387
Study: 20078802

Group type: EXPERIMENTAL
Intervention: Therapeutic suggestion
Number of subjects: 67

Group type: COMPARATOR
Intervention: Story (prosody control)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard operating room noise
Number of subjects: 67
Study: 18408389

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Autologous rectus fascia sling
Number of subjects: 100
Study: 15807809

Group type: EXPERIMENTAL
Intervention: Age group 25-35 years
Number of subjects: 80

Group type: COMPARATOR
Intervention: Age group 50-65 years
Number of subjects: 80
Study: 11961629

Group type: EXPERIMENTAL
Intervention: Local wound infiltration with 10 ml of 0.5% bupivacaine (group I, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Instillation of the extraperitoneal space with 40 ml of 0.25% bupivacaine (group II, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group II (extraperitoneal instillation)
Number of subjects: 100
Study: 10510158

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pantoprazole (80 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7493428

Group type: EXPERIMENTAL
Intervention: Water restriction (200 ml/day) during low-sodium diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hydrated group (1800 ml/day water intake) during low-sodium diet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both groups (hydrated and dehydrated)
Number of subjects: 6
Study: 1372508

Group type: EXPERIMENTAL
Intervention: Penicillin (5 mu twice, 6 hours apart)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221

Group type: COMPARATOR
Intervention: No treatment (without penicillin or placebo)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Infants born soon after PROM
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Infants born after prolonged PROM
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 221
Study: 3876579

Group type: EXPERIMENTAL
Intervention: Analgesic electrical stimulation (AES)
Number of subjects: 25
Study: 31290227

Group type: EXPERIMENTAL
Intervention: Resilience-based intervention programme
Number of subjects: 285

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 285
Study: 30325721

Group type: EXPERIMENTAL
Intervention: Patient expression of emotions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Companion questions about psychosocial and lifestyle topics
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: RIAS overall patient-centeredness score
Number of subjects: 79
Study: 27637570

Group type: EXPERIMENTAL
Intervention: Breathe Right® external nasal dilator
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Turbine® internal nasal dilator
Number of subjects: 15

Group type: COMPARATOR
Intervention: No device (control)
Number of subjects: 15
Study: 23713923

Group type: EXPERIMENTAL
Intervention: Translucent occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lightproof occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both occlusion types
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 0
Study: 21941790

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 46
Study: 19135078

Group type: EXPERIMENTAL
Intervention: Visual stimuli composed of spatially alternating stripes containing different luminances or motion signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neon-color-spreading paradigm
Number of subjects: 0
Study: 17148971

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 534

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study: 15480323

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 2 years
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 1 year
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 11735682

Group type: EXPERIMENTAL
Intervention: Multifactorial injury prevention programme in soccer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ankle disk training combined with thorough warm-up in European team handball
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ankle supports (semirigid orthoses or air-cast braces) in high-risk sports
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shock-absorbing insoles in footwear
Number of subjects: 0
Study: 9059210

Group type: EXPERIMENTAL
Intervention: Continuous brachial plexus infusion of butorphanol 6 mg with 0.5% mepivacaine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bolus of butorphanol 1 mg with 1.5% mepivacaine and continuous brachial plexus infusion of 0.5% mepivacaine with butorphanol 6 mg
Number of subjects: 2
Study: 8440540

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intralipid infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3512124

Group type: EXPERIMENTAL
Intervention: Moricizine (10 mg/kg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 50
Study: 29353551

Group type: EXPERIMENTAL
Intervention: Messages highlighting human responsibility with a distal temporal frame
Number of subjects: 355

Group type: COMPARATOR
Intervention: Messages highlighting human responsibility with an imminent temporal frame
Number of subjects: 355

Group type: COMPARATOR
Intervention: Messages highlighting animal responsibility
Number of subjects: 355
Study: 26259053

Group type: EXPERIMENTAL
Intervention: 20 Hz TENS
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 75 Hz TENS
Number of subjects: 81

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 81
Study: 24396838

Group type: EXPERIMENTAL
Intervention: Pink-veneered zirconia abutments and all-ceramic crowns
Number of subjects: 0

Group type: COMPARATOR
Intervention: White zirconia abutments (control group)
Number of subjects: 0
Study: 22429002

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bimanual training (BIM)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both CIMT and BIM
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 63
Study: 20631478

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18775020

Group type: EXPERIMENTAL
Intervention: AZD7371 20 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: AZD7371 5 mg
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: AZD7371
Number of subjects: 402
Study: 16214830

Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg bid
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: ivabradine 10 mg bid
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg bid
Number of subjects: 939

Group type: COMPARATOR
Intervention: atenolol 50 mg od
Number of subjects: 939

Group type: COMPARATOR
Intervention: atenolol 100 mg
Number of subjects: 939
Study: 12023136

Group type: EXPERIMENTAL
Intervention: 125I (144 Gy)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 103Pd (125 Gy, NIST‐1999)
Number of subjects: 82
Study: 10503809

Group type: EXPERIMENTAL
Intervention: Aminoguanidine (two dose levels)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599
Study: 8604442

Group type: EXPERIMENTAL
Intervention: Invasive approach
Number of subjects: 57

Group type: COMPARATOR
Intervention: Noninvasive approach
Number of subjects: 57
Study: 1777372

Group type: EXPERIMENTAL
Intervention: Atenolol (50 or 100 mg once daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Captopril (25 or 50 mg twice daily)
Number of subjects: 18
Study: 6118768

Group type: EXPERIMENTAL
Intervention: exercise training
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: extra advice
Number of subjects: 129

Group type: COMPARATOR
Intervention: normal treatment (control)
Number of subjects: 129
Study: 31544381

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with comprehensive rehabilitation therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comprehensive rehabilitation therapy alone (Control group)
Number of subjects: 62
Study: 27996217

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program, 12-week, twice a week, 60-minute sessions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program
Number of subjects: 32
Study: 25367691

Group type: EXPERIMENTAL
Intervention: R. emodi capsules (two times a day, two days before menstruation and continued for the first three days of menstruation)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mefenamic acid capsules (three times a day on the same protocol)
Number of subjects: 45
Study: 23652600

Group type: EXPERIMENTAL
Intervention: Complete ST-segment resolution (>70%)
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Partial ST-segment resolution (30%-70%)
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Absent ST-segment resolution (<30%)
Number of subjects: 2484
Study: 21295433

Group type: EXPERIMENTAL
Intervention: Computerized self-monitoring with Basic feedback
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Enhanced behavioral feedback
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study: 19299239

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/day orally)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/day orally)
Number of subjects: 130
Study: 17534819

Group type: EXPERIMENTAL
Intervention: Topical levofloxacin (three times on the day before surgery and seven times on the day of surgery)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin (200 mg twice on the day before surgery and 200 mg at 3 hours before surgery)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined topical and oral levofloxacin (according to the above schedules)
Number of subjects: 36
Study: 15486815

Group type: EXPERIMENTAL
Intervention: 100 mg acarbose three times a day for eight weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11600560

Group type: EXPERIMENTAL
Intervention: Triglyceride infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study: 9844752

Group type: EXPERIMENTAL
Intervention: Bright light (BL; 5000-8000 lux) for 2 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dim light (DL; 300 lux) for 2 weeks
Number of subjects: 22
Study: 7863754

Group type: EXPERIMENTAL
Intervention: Patients who did not attend treatment regularly (36 patients)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Patients who attended treatment regularly but had missed at least one treatment (50 patients)
Number of subjects: 1175
Study: 2771867

Group type: EXPERIMENTAL
Intervention: flunitrazepam 1 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: triazolam 0.25 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study: 782651

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31746642

Group type: EXPERIMENTAL
Intervention: Lip repair and soft palate closure at 4 months and hard palate closure at 12 months (Arm A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Closure of both the soft and hard palate at 12 months (Arm C)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Finnish center
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Swedish centers
Number of subjects: 112
Study: 30644326

Group type: EXPERIMENTAL
Intervention: Ropinirole (agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amisulpride
Number of subjects: 0
Study: 28160101

Group type: EXPERIMENTAL
Intervention: Low interference group (blocked observation)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Medium interference group (semi-interleaved observation)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High interference group (interleaved observation)
Number of subjects: 3
Study: 26450585

Group type: EXPERIMENTAL
Intervention: 15-item version of the Questionnaire about the Process of Recovery (QPR)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: 22-item version of the Questionnaire about the Process of Recovery (QPR)
Number of subjects: 487
Study: 22981241

Group type: EXPERIMENTAL
Intervention: Zinc gluconate 10 mg for 60 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 20212518

Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Nortriptyline (tricyclic antidepressant)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR and STin4 polymorphisms
Number of subjects: 811
Study: 18564168

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 20